Trevi Therapeutics (NASDAQ:TRVI) Announces Quarterly Earnings Results

Trevi Therapeutics (NASDAQ:TRVI) released its quarterly earnings results on Tuesday. The company reported an earnings per share (EPS) of ($0.11) for the quarter, which was better than analysts' expectations of ($0.12), beating the consensus estimate by $0.01 according to Zacks.

Trevi Therapeutics Stock Performance

On Tuesday, Trevi Therapeutics' stock saw a slight increase of 0.8%, trading up $0.06 to reach $6.60 during mid-day trading. The trading volume was 2,202,888 shares, significantly higher than the average volume of 968,847 shares. Trevi Therapeutics has a market capitalization of approximately $506.93 million, with a negative price-to-earnings ratio of -14.99 and a beta of 0.90. The stock has experienced a 12-month low of $2.30 and a high of $7.39, with a 50-day moving average of $4.39 and a 200-day moving average of $3.66.

Insider Transactions

In related news, on March 10th, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics at an average price of $6.75, totaling about $548,862.75. After this transaction, Simon’s ownership in the company decreased by 51.39%, leaving him with 76,900 shares valued at around $519,075. This transaction was reported to the Securities and Exchange Commission, where further details can be found. Insiders currently hold 24.37% of the company's shares.

Analyst Opinions on Trevi Therapeutics

Trevi Therapeutics has received attention from several research analysts. On March 11th, Oppenheimer increased its target price for Trevi Therapeutics from $12.00 to $20.00 and rated the stock as "outperform." HC Wainwright also raised their target price from $7.50 to $12.50 and assigned a "buy" rating on March 10th. Additionally, Needham & Company LLC increased its target price from $8.00 to $25.00 while issuing a "buy" rating on the same day. D. Boral Capital reiterated a "buy" rating with a target price of $21.00 on March 7th. Raymond James upgraded their rating from "outperform" to "strong-buy" and set a new target price of $29.00 on March 10th. Overall, seven analysts have rated Trevi Therapeutics as a buy with three giving it a strong buy rating. The average consensus rating is "Buy" with a price target of $15.94.

Company Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing its therapy, Haduvio, to treat chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). This treatment aims to target both central and peripheral nervous systems.

Earnings, Stocks, Analysis